Personalis PREDICT-DNA study links post-neoadjuvant ctDNA to 4x-9x higher breast cancer relapse risk

Reuters03-12

<a href="https://laohu8.com/S/PSNL">Personalis</a> PREDICT-DNA study links post-neoadjuvant ctDNA to 4x-9x higher breast cancer relapse risk

Personalis reported results from the prospective PREDICT-DNA study in the Journal of Clinical Oncology evaluating the NeXT Personal ctDNA assay for monitoring molecular residual disease in triple-negative and HER2+ breast cancer after neoadjuvant therapy. The study followed 227 patients across more than 24 U.S. cancer centers and found that detectable ctDNA after neoadjuvant therapy was associated with a 4 to 9 times higher likelihood of relapse. Personalis said 55% of post-neoadjuvant ctDNA detections occurred below 100 parts per million. In analyses described by the company, ctDNA status after neoadjuvant therapy was a stronger predictor of recurrence than pathologic complete response. Richard Chen and Ben Park commented on the findings and their potential use in risk stratification and treatment monitoring.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603120600BIZWIRE_USPR_____20260312_BW182084) on March 12, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618138310?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 18:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618138310","market":"nz","top_or_hot":-1,"title":"Personalis PREDICT-DNA study links post-neoadjuvant ctDNA to 4x-9x higher breast cancer relapse risk","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PSNL\">Personalis</a> PREDICT-DNA study links post-neoadjuvant ctDNA to 4x-9x higher breast cancer relapse risk\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Personalis reported results from the prospective PREDICT-DNA study in the Journal of Clinical Oncology evaluating the NeXT Personal ctDNA assay for monitoring molecular residual disease in triple-negative and HER2+ breast cancer after neoadjuvant therapy. The study followed 227 patients across more than 24 U.S. cancer centers and found that detectable ctDNA after neoadjuvant therapy was associated with a 4 to 9 times higher likelihood of relapse. Personalis said 55% of post-neoadjuvant ctDNA detections occurred below 100 parts per million. In analyses described by the company, ctDNA status after neoadjuvant therapy was a stronger predictor of recurrence than pathologic complete response. Richard Chen and Ben Park commented on the findings and their potential use in risk stratification and treatment monitoring.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603120600BIZWIRE_USPR_____20260312_BW182084) on March 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Personalis PREDICT-DNA study links post-neoadjuvant ctDNA to 4x-9x higher breast cancer relapse risk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPersonalis PREDICT-DNA study links post-neoadjuvant ctDNA to 4x-9x higher breast cancer relapse risk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-12 18:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PSNL\">Personalis</a> PREDICT-DNA study links post-neoadjuvant ctDNA to 4x-9x higher breast cancer relapse risk\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Personalis reported results from the prospective PREDICT-DNA study in the Journal of Clinical Oncology evaluating the NeXT Personal ctDNA assay for monitoring molecular residual disease in triple-negative and HER2+ breast cancer after neoadjuvant therapy. The study followed 227 patients across more than 24 U.S. cancer centers and found that detectable ctDNA after neoadjuvant therapy was associated with a 4 to 9 times higher likelihood of relapse. Personalis said 55% of post-neoadjuvant ctDNA detections occurred below 100 parts per million. In analyses described by the company, ctDNA status after neoadjuvant therapy was a stronger predictor of recurrence than pathologic complete response. Richard Chen and Ben Park commented on the findings and their potential use in risk stratification and treatment monitoring.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603120600BIZWIRE_USPR_____20260312_BW182084) on March 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL1YQvjF:1","article_id":"2618138310","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618138310","pubTimestamp":1773309673,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Personalis reported results from the prospective PREDICT-DNA study in the Journal of Clinical Oncology evaluating the NeXT Personal ctDNA assay for monitoring molecular residual disease in triple-negative and HER2+ breast cancer after neoadjuvant therapy. The study followed 227 patients across more than 24 U.S. cancer centers and found that detectable ctDNA after neoadjuvant therapy was associated with a 4 to 9 times higher likelihood of relapse. Personalis said 55% of post-neoadjuvant ctDNA detections occurred below 100 parts per million. In analyses described by the company, ctDNA status after neoadjuvant therapy was a stronger predictor of recurrence than pathologic complete response. Richard Chen and Ben Park commented on the findings and their potential use in risk stratification and treatment monitoring.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","PSNL":"Personalis"},"translate_title":"Personalis PREDICT-DNA研究将新辅助后ctDNA与乳腺癌复发风险增加4x-9x联系起来","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSNL":0.9},"content_text":"Personalis PREDICT-DNA study links post-neoadjuvant ctDNA to 4x-9x higher breast cancer relapse risk\n    \n\n        Personalis reported results from the prospective PREDICT-DNA study in the Journal of Clinical Oncology evaluating the NeXT Personal ctDNA assay for monitoring molecular residual disease in triple-negative and HER2+ breast cancer after neoadjuvant therapy. The study followed 227 patients across more than 24 U.S. cancer centers and found that detectable ctDNA after neoadjuvant therapy was associated with a 4 to 9 times higher likelihood of relapse. Personalis said 55% of post-neoadjuvant ctDNA detections occurred below 100 parts per million. In analyses described by the company, ctDNA status after neoadjuvant therapy was a stronger predictor of recurrence than pathologic complete response. Richard Chen and Ben Park commented on the findings and their potential use in risk stratification and treatment monitoring.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603120600BIZWIRE_USPR_____20260312_BW182084) on March 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618138310","isCrawlerRequest":true}